1167056-92-9 Usage
General Description
1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid, 6-chloro- is a chemical compound with the molecular formula C10H6ClNO2. It is a derivative of pyrrolo[2,3-b]pyridine, a heterocyclic compound with a pyridine ring fused to a pyrrole ring. The addition of a carboxylic acid group and a chlorine atom at the 6th position of the pyrrolo[2,3-b]pyridine structure gives this compound unique properties and potential applications in pharmaceuticals and agrochemicals. It may be used in the synthesis of various biologically active compounds and as a building block for drug discovery and development. Its structure and chemical properties make it an interesting target for further research and exploration of its potential uses in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1167056-92-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,7,0,5 and 6 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1167056-92:
(9*1)+(8*1)+(7*6)+(6*7)+(5*0)+(4*5)+(3*6)+(2*9)+(1*2)=159
159 % 10 = 9
So 1167056-92-9 is a valid CAS Registry Number.
1167056-92-9Relevant articles and documents
N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS
-
Page/Page column 111, (2021/05/07)
The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).
